Cover Image
市場調查報告書

Octapharma AG的產品平台分析

Octapharma AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226221
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Octapharma AG的產品平台分析 Octapharma AG - Product Pipeline Review - 2015
出版日期: 2015年04月30日 內容資訊: 英文 40 Pages
簡介

本報告提供Octapharma AG的治療藥開發平台現狀與各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Octapharma AG的基本資料

Octapharma AG概要

  • 主要資訊
  • 企業資料

Octapharma AG:R&D概要

  • 主要的治療範圍

Octapharma AG:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Octapharma AG:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式

Octapharma AG:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Octapharma AG:藥物簡介

  • Human-cl rhFVIII
  • 血漿
  • 免疫球蛋白
  • 濃縮纖維蛋白原
  • 人類成長因子
  • Lyoplas
  • NewNorm

Octapharma AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Octapharma AG:最近的開發平台趨勢

Octapharma AG:暫停中的計劃

Octapharma AG:企業發表

Octapharma AG:總公司和子公司的所在地

Octapharma AG:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07010CDB

Summary

Global Markets Direct's, 'Octapharma AG - Product Pipeline Review - 2015', provides an overview of the Octapharma AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Octapharma AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Octapharma AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Octapharma AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Octapharma AG's pipeline products

Reasons to buy

  • Evaluate Octapharma AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Octapharma AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Octapharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Octapharma AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Octapharma AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Octapharma AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Octapharma AG Snapshot
    • Octapharma AG Overview
    • Key Information
    • Key Facts
  • Octapharma AG - Research and Development Overview
    • Key Therapeutic Areas
  • Octapharma AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Octapharma AG - Pipeline Products Glance
    • Octapharma AG - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Octapharma AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Octapharma AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Octapharma AG - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Octapharma AG - Drug Profiles
    • coagulation factor VIII (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plasma (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fibrinogen concentrate (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NewNorm
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Human Growth Factor
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Octapharma AG - Pipeline Analysis
    • Octapharma AG - Pipeline Products by Target
    • Octapharma AG - Pipeline Products by Route of Administration
    • Octapharma AG - Pipeline Products by Molecule Type
    • Octapharma AG - Pipeline Products by Mechanism of Action
  • Octapharma AG - Recent Pipeline Updates
  • Octapharma AG - Dormant Projects
  • Octapharma AG - Company Statement
  • Octapharma AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Octapharma AG - Key Manufacturing Facilities
    • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Octapharma AG, Key Information
  • Octapharma AG, Key Facts
  • Octapharma AG - Pipeline by Indication, 2015
  • Octapharma AG - Pipeline by Stage of Development, 2015
  • Octapharma AG - Monotherapy Products in Pipeline, 2015
  • Octapharma AG - Pre-Registration, 2015
  • Octapharma AG - Phase III, 2015
  • Octapharma AG - Phase II, 2015
  • Octapharma AG - Preclinical, 2015
  • Octapharma AG - Unknown, 2015
  • Octapharma AG - Pipeline by Target, 2015
  • Octapharma AG - Pipeline by Route of Administration, 2015
  • Octapharma AG - Pipeline by Molecule Type, 2015
  • Octapharma AG - Pipeline Products by Mechanism of Action, 2015
  • Octapharma AG - Recent Pipeline Updates, 2015
  • Octapharma AG - Dormant Developmental Projects,2015
  • Octapharma AG, Other Locations
  • Octapharma AG, Subsidiaries
  • Octapharma AG, Key Manufacturing Facilities

List of Figures

  • Octapharma AG - Pipeline by Top 10 Indication, 2015
  • Octapharma AG - Pipeline by Stage of Development, 2015
  • Octapharma AG - Monotherapy Products in Pipeline, 2015
  • Octapharma AG - Pipeline by Top 10 Target, 2015
  • Octapharma AG - Pipeline by Top 10 Route of Administration, 2015
  • Octapharma AG - Pipeline by Top 10 Molecule Type, 2015
  • Octapharma AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top